The discovery could lead to targeted therapy in triple negative breast cancer patients.
Basal-like breast cancer (BLBC), more commonly known as triple-negative breast cancer, is a deadly disease with poor prognosis. Highly prevelant among younger and African-American women, the disease is associated with extensive metastasis early in the disease. Now, scientists at the Boston University School of Medicine and the University of Cyprus have identified a biomarker, a receptor called IL13RA2; high levels of expression of this receptor could indicate worse progression-free survival. Women who had high expression of IL13RA2 also presented with increased lung metastases.
In their study published in Breast Cancer Research the authors show that depletion of this receptor in metastatic breast cancer cells reduced growth of the primary tumor and also had a significant impact on preventing lung metastases. A genomewide transcription analysis showed that knowckdown of IL13AR2 and treatment of breast cancer cells with IL2 resulted in a STAT6-dependent TP63 signaling, which could be responsible for the reduced lung metastases of these cancerous cells.
"This discovery offers a glimmer of hope for patients stricken with BLBC. Personalized cancer therapies could be developed by targeting breast cancer cells that express copious levels of IL13RA2," explained corresponding author Sam Thiagalingam, PhD, in an interview. Considering that IL13RA2 is also expressed in other deadly cancers such as pancreatic, brain, and ovarian cancer, these results have a much wider implication.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More